Global InformationPhilip Kantoff information
Philip Kantoff | |
|---|---|
 | |
| Nationality | American |
| Citizenship | American |
| Alma mater |
|
| Scientific career | |
| Institutions |
|
| Website | Philip Kantoff |
Philip W. Kantoff is a medical oncologist.[2] He is the chairman and chief executive officer (CEO) of Convergent Therapeutics.[3] He served as the Chairman of Medicine at Memorial Sloan Kettering Cancer Center between 2015 and 2021.[4][5] He is best known for his contributions to the impact of DNA abnormalities in prostate cancer and the discovery of therapies for metastatic hormone-sensitive prostate cancer.
- ^ Team, Onclive (27 December 2015). "New Post at MSK Offers Kantoff Another Platform for Leadership in GU Field". OncLive. Vol. 17/No. 1. 17. Retrieved 2021-04-26.
- ^ Szathmary, Zoe (2017-08-23). "Prostate cancer symptoms and warning signs". Fox News. Retrieved 2020-06-11.
- ^ Andrew Humphreys (2021-08-14). "New CEO for Convergent". PharmaLive. Retrieved 2021-10-20.
- ^ York, New; NY. "Philip W. Kantoff, MD, Named Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center | Memorial Sloan Kettering Cancer Center". www.mskcc.org. Retrieved 2021-10-21.
- ^ "Philip W. Kantoff, MD". Dana–Farber Cancer Institute. 2011-07-20. Retrieved 2020-06-11.